Previsioni

Il prezzo obiettivo medio degli analisti è +4,29€ (+227,48%). La mediana è +4,29€ (+227,48%).

Acquista	2
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Insider purchase at OKYO Pharma: CSO Raj Patil increases holdings

Raj Patil, chief scientific officer of OKYO Pharma, bought 3,363 common shares on the NASDAQ at $1.49 each, bringing his holdings to 20,030 shares. OKYO Pharma is preparing to start a global phase‑3 trial in the second half of the year with about 111 patients to evaluate a single dose of urcosimod for neuropathic corneal pain. » Altro su de.investing.com
OKYO Pharma: CEO Robert J. Dempsey buys 15,000 shares at $1.54

Chief Executive Officer Robert J. Dempsey purchased 15,000 common shares of OKYO Pharma on the open market at $1.54 per share on the NASDAQ. OKYO Pharma is listed on the Nasdaq Capital Market and plans to start a global phase‑3 single‑dose study of urcosimod for neuropathic corneal pain in the second half of the year with about 111 patients. The company is in the clinical development phase for anterior segment eye therapies. » Altro su de.investing.com
OKYO Pharma: chief development officer Gary S. Jacob buys 3,500 shares

Gary S. Jacob, chief development officer and director of OKYO Pharma, purchased 3,500 common shares at $1.40 each on the Nasdaq, bringing his total holding to 112,420 shares. OKYO Pharma’s common stock is listed on the Nasdaq Capital Market. The biopharmaceutical company plans to start a global, registration‑enabling Phase 3 study of urcosimod for the treatment of neuropathic corneal pain in the second half of the year, likely with around 111 patients and a single‑dose regimen. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, OKYO PHARMA LTD Aktie ha registrato ricavi pari a 0,00€ e un utile netto di −5,50M€

(EUR)	mar 2026	YoY
Ricavi	0,00	-
Utile lordo	−807,75	-
Utile netto	−5,50M	-
EBITDA	−5,53M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+49,41M€
Numero di azioni	38,37M
Massimo/minimo a 52 settimane	+2,75€ - +1,15€
Dividendi	No
Beta	0,05
Rapporto P/E	−6,27
Rapporto PEG	+0,05
Rapporto P/B	+4,55
Rapporto P/S	0,00

Profilo aziendale

OKYO Pharma Limited, ein präklinisches biopharmazeutisches Unternehmen, entwickelt im Vereinigten Königreich Therapeutika für Patienten, die an entzündlichen Augenerkrankungen und Augenschmerzen leiden. Zu seinem führenden Produkt gehört OK-101 zur Behandlung von Erkrankungen des trockenen Auges. Das Unternehmen entwickelt außerdem OK-201, einen präklinischen Kandidaten für ein lipidiertes Peptidanalogon aus Rindernebennierenmark zur Behandlung von neuropathischen Augenschmerzen. OKYO Pharma Limited wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in London, Vereinigtes Königreich.

Nome	OKYO PHARMA LTD Aktie
CEO	Robert J. Dempsey
Sede centrale	London, gl Regno Unito
Sito web	okyopharma.com
Industria	Prodotti alimentari
Quotazione in borsa	17/05/2022
Dipendenti	5